Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
Although co-administration of posaconazole with ruxolitinib resulted in a statistically significant increase in ruxolitinib systemic exposure, the magnitude of this interaction was clinically moderate. Although ruxolitinib dose adjustment may not be routinely required when used concomitantly with posaconazole, close monitoring for ruxolitinib-related adverse effects is recommended under this combination therapy setting.
Authors
- Beibei Liang (ORCID: https://orcid.org/0000-0002-5363-6315)
- J. Zeng (ORCID: https://orcid.org/0000-0002-3903-0157)
- Yun Cai (ORCID: https://orcid.org/0000-0001-6687-9984)
- Songhua Luan
- Liping Dou (ORCID: https://orcid.org/0000-0001-7352-9560)
- Fei Li (ORCID: https://orcid.org/0000-0002-7679-1641)
- Na Zhang (ORCID: https://orcid.org/0000-0003-2270-3463)
Institutions
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1093/jac/dkaf398
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00